Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 308

1.

Combining two developmental screening tests to improve predictive accuracy.

Camp BW, Bonnell LN.

Acad Pediatr. 2019 Jun 17. pii: S1876-2859(19)30297-9. doi: 10.1016/j.acap.2019.06.010. [Epub ahead of print]

PMID:
31220593
2.

Giving pork the chop: Response inhibition training to reduce meat intake.

Camp B, Lawrence NS.

Appetite. 2019 Oct 1;141:104315. doi: 10.1016/j.appet.2019.06.007. Epub 2019 Jun 6.

PMID:
31176649
3.

Diagnosis of genetic diseases in seriously ill children by rapid whole-genome sequencing and automated phenotyping and interpretation.

Clark MM, Hildreth A, Batalov S, Ding Y, Chowdhury S, Watkins K, Ellsworth K, Camp B, Kint CI, Yacoubian C, Farnaes L, Bainbridge MN, Beebe C, Braun JJA, Bray M, Carroll J, Cakici JA, Caylor SA, Clarke C, Creed MP, Friedman J, Frith A, Gain R, Gaughran M, George S, Gilmer S, Gleeson J, Gore J, Grunenwald H, Hovey RL, Janes ML, Lin K, McDonagh PD, McBride K, Mulrooney P, Nahas S, Oh D, Oriol A, Puckett L, Rady Z, Reese MG, Ryu J, Salz L, Sanford E, Stewart L, Sweeney N, Tokita M, Van Der Kraan L, White S, Wigby K, Williams B, Wong T, Wright MS, Yamada C, Schols P, Reynders J, Hall K, Dimmock D, Veeraraghavan N, Defay T, Kingsmore SF.

Sci Transl Med. 2019 Apr 24;11(489). pii: eaat6177. doi: 10.1126/scitranslmed.aat6177.

PMID:
31019026
4.

Barriers and Facilitators of Colorectal Cancer Screening in a Federally Qualified Health Center (FQHC).

Ylitalo KR, Camp BG, Umstattd Meyer MR, Barron LA, Benavidez G, Hess B, Laschober R, Griggs JO.

J Am Board Fam Med. 2019 Mar-Apr;32(2):180-190. doi: 10.3122/jabfm.2019.02.180205.

5.

A new cross-platform architecture for epi-info software suite.

Camp B, Mandivarapu JK, Ramamurthy N, Wingo J, Bourgeois AG, Cao X, Sunderraman R.

BMC Bioinformatics. 2018 Oct 22;19(Suppl 11):359. doi: 10.1186/s12859-018-2334-8.

6.

Cannabis and crash responsibility while driving below the alcohol per se legal limit.

Romano E, Voas RB, Camp B.

Accid Anal Prev. 2017 Nov;108:37-43. doi: 10.1016/j.aap.2017.08.003. Epub 2017 Sep 6.

PMID:
28841409
7.

The Impact of Cumulative Sociodemographic Risk Factors on the Home Environment and Vocabulary in Early Childhood.

Shriver AE, Bonnell LN, Camp BW.

Adv Pediatr. 2017 Aug;64(1):371-380. doi: 10.1016/j.yapd.2017.03.001. Review. No abstract available.

PMID:
28688598
8.

Treatment of metastatic cutaneous Crohn disease with certolizumab.

Kiuru M, Camp B, Adhami K, Jacob V, Magro C, Wildman H.

Dermatol Online J. 2015 Nov 18;21(11). pii: 13030/qt17z6j2hv.

PMID:
26632928
9.

Isolation of Leclercia adecarboxylata from a patient with a subungual splinter.

Allawh R, Camp BJ.

Dermatol Online J. 2015 Aug 15;21(8). pii: 13030/qt2hb6x3c9.

PMID:
26437172
10.

Navigating to new frontiers in behavioral neuroscience: traditional neuropsychological tests predict human performance on a rodent-inspired radial-arm maze.

Mennenga SE, Baxter LC, Grunfeld IS, Brewer GA, Aiken LS, Engler-Chiurazzi EB, Camp BW, Acosta JI, Braden BB, Schaefer KR, Gerson JE, Lavery CN, Tsang CW, Hewitt LT, Kingston ML, Koebele SV, Patten KJ, Ball BH, McBeath MK, Bimonte-Nelson HA.

Front Behav Neurosci. 2014 Sep 9;8:294. doi: 10.3389/fnbeh.2014.00294. eCollection 2014.

11.

Pharmacological blockade of the aromatase enzyme, but not the androgen receptor, reverses androstenedione-induced cognitive impairments in young surgically menopausal rats.

Mennenga SE, Koebele SV, Mousa AA, Alderete TJ, Tsang CW, Acosta JI, Camp BW, Demers LM, Bimonte-Nelson HA.

Steroids. 2015 Jul;99(Pt A):16-25. doi: 10.1016/j.steroids.2014.08.010. Epub 2014 Aug 23.

12.

A case of protothecosis in a patient with multiple myeloma.

Figueroa CJ, Camp BJ, Varghese GI, Miranda E, Querfeld C, Hassoun H, Kamboj M, Pulitzer MP.

J Cutan Pathol. 2014 May;41(5):409-13. doi: 10.1111/cup.12338. No abstract available.

PMID:
24758253
13.

Discussion of 'The overall program effects of California's 3-Tier Assessment System pilot on crashes and mobility among senior drivers' [J Safety Res 47 (2013) 1-8].

Hennessy DF, Camp BJ.

J Safety Res. 2014 Feb;48:111-5. doi: 10.1016/j.jsr.2013.12.004. Epub 2013 Dec 28. No abstract available.

PMID:
24529099
14.

Evaluating developmental screening in clinical practice.

Dawson P, Camp BW.

SAGE Open Med. 2014 Dec 22;2:2050312114562579. doi: 10.1177/2050312114562579. eCollection 2014.

15.

The overall program effects of California's 3-Tier Assessment System pilot on crashes and mobility among senior drivers.

Camp BJ.

J Safety Res. 2013 Dec;47:1-8. doi: 10.1016/j.jsr.2013.06.002. Epub 2013 Jul 16.

PMID:
24237864
16.

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.

Xu S, Cecilia Santini G, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.

PLoS One. 2013 Nov 6;8(11):e79752. doi: 10.1371/journal.pone.0079752. eCollection 2013.

17.

Levamisole toxicity mimicking autoimmune disease.

Strazzula L, Brown KK, Brieva JC, Camp BJ, Frankel HC, Kissin E, Mahlberg MJ, Mina MA, Pomeranz MK, Brownell I, Kroshinsky D.

J Am Acad Dermatol. 2013 Dec;69(6):954-9. doi: 10.1016/j.jaad.2013.07.037. Epub 2013 Sep 24.

PMID:
24075227
18.

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K.

Mol Cancer Ther. 2013 Sep;12(9):1763-73. doi: 10.1158/1535-7163.MCT-13-0123. Epub 2013 Jul 5. Erratum in: Mol Cancer Ther. 2015 Jul;14(7):1762. De Bryune, Elke [Corrected to De Bruyne, Elke].

19.

Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.

Xu S, De Veirman K, Evans H, Santini GC, Vande Broek I, Leleu X, De Becker A, Van Camp B, Croucher P, Vanderkerken K, Van Riet I.

Acta Pharmacol Sin. 2013 May;34(5):699-709. doi: 10.1038/aps.2012.182. Epub 2013 Apr 8.

20.

An update on the cognitive impact of clinically-used hormone therapies in the female rat: models, mazes, and mechanisms.

Acosta JI, Hiroi R, Camp BW, Talboom JS, Bimonte-Nelson HA.

Brain Res. 2013 Jun 13;1514:18-39. doi: 10.1016/j.brainres.2013.01.016. Epub 2013 Jan 16.

21.

Adult T-cell leukemia/lymphoma with follicular mucinosis: an unusual histopathological finding and a commentary.

Camp B, Horwitz S, Pulitzer MP.

J Cutan Pathol. 2012 Sep;39(9):861-5. doi: 10.1111/j.1600-0560.2012.01953.x. Review.

PMID:
22905687
22.

Cutaneous macroglobulinosis: a case series.

Camp BJ, Magro CM.

J Cutan Pathol. 2012 Oct;39(10):962-70. doi: 10.1111/j.1600-0560.2012.01983.x. Epub 2012 Aug 11.

PMID:
22882527
23.

Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types.

Guduric-Fuchs J, O'Connor A, Camp B, O'Neill CL, Medina RJ, Simpson DA.

BMC Genomics. 2012 Aug 1;13:357. doi: 10.1186/1471-2164-13-357.

24.

In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.

Xu S, De Becker A, De Raeve H, Van Camp B, Vanderkerken K, Van Riet I.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):391-7. doi: 10.1016/j.bbrc.2012.06.118. Epub 2012 Jul 6.

PMID:
22771324
25.

High serum androstenedione levels correlate with impaired memory in the surgically menopausal rat: a replication and new findings.

Camp BW, Gerson JE, Tsang CW, Villa SR, Acosta JI, Blair Braden B, Hoffman AN, Conrad CD, Bimonte-Nelson HA.

Eur J Neurosci. 2012 Oct;36(8):3086-95. doi: 10.1111/j.1460-9568.2012.08194.x. Epub 2012 Jul 3.

26.

Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models.

Digby GJ, Noetzel MJ, Bubser M, Utley TJ, Walker AG, Byun NE, Lebois EP, Xiang Z, Sheffler DJ, Cho HP, Davis AA, Nemirovsky NE, Mennenga SE, Camp BW, Bimonte-Nelson HA, Bode J, Italiano K, Morrison R, Daniels JS, Niswender CM, Olive MF, Lindsley CW, Jones CK, Conn PJ.

J Neurosci. 2012 Jun 20;32(25):8532-44. doi: 10.1523/JNEUROSCI.0337-12.2012.

27.

Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway.

Xu S, Evans H, Buckle C, De Veirman K, Hu J, Xu D, Menu E, De Becker A, Vande Broek I, Leleu X, Camp BV, Croucher P, Vanderkerken K, Van Riet I.

Leukemia. 2012 Dec;26(12):2546-9. doi: 10.1038/leu.2012.126. Epub 2012 May 8. No abstract available.

PMID:
22652628
28.

The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.

Lemaire M, Fristedt C, Agarwal P, Menu E, Van Valckenborgh E, De Bruyne E, Österborg A, Atadja P, Larsson O, Axelson M, Van Camp B, Jernberg-Wiklund H, Vanderkerken K.

Clin Cancer Res. 2012 Apr 15;18(8):2230-9. doi: 10.1158/1078-0432.CCR-11-1764. Epub 2012 Mar 5.

29.

Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.

Hu J, Dang N, Menu E, De Bruyne E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K.

Blood. 2012 Jan 19;119(3):826-37. doi: 10.1182/blood-2011-07-366492. Epub 2011 Nov 29. Erratum in: Blood. 2014 Jul 24;124(4):663. De Bryune, Elke [corrected to De Bruyne, Elke].

30.

Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.

Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.

Stem Cells. 2012 Feb;30(2):266-79. doi: 10.1002/stem.787.

31.

Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation.

Xu D, Hu J, Xu S, De Bruyne E, Menu E, Van Camp B, Vanderkerken K, Van Valckenborgh E.

Leukemia. 2012 Jun;26(6):1402-5. doi: 10.1038/leu.2011.332. Epub 2011 Nov 18. No abstract available.

PMID:
22094583
32.

Donor-derived lymphomatoid papulosis in a stem-cell transplantation recipient.

Camp BJ, Busam KJ, Brownell I, Koehne G, Hedvat C, Pulitzer MP.

J Clin Oncol. 2011 Dec 10;29(35):e855-8. doi: 10.1200/JCO.2011.37.7101. Epub 2011 Oct 31. No abstract available.

33.

An improved harvest and in vitro expansion protocol for murine bone marrow-derived mesenchymal stem cells.

Xu S, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.

J Biomed Biotechnol. 2010;2010:105940. doi: 10.1155/2010/105940. Epub 2010 Dec 20.

34.

Relationship between the cognitive environment and vocabulary development during the second year of life.

Camp BW, Cunningham M, Berman S.

Arch Pediatr Adolesc Med. 2010 Oct;164(10):950-6. doi: 10.1001/archpediatrics.2010.169.

PMID:
20921353
35.

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K.

Blood. 2010 Sep 2;116(9):1524-7. doi: 10.1182/blood-2010-02-269126. Epub 2010 Jun 7.

36.

Applying Bayesian analysis to evaluation of developmental screening.

Camp BW.

J Dev Behav Pediatr. 2009 Dec;30(6):583-92. doi: 10.1097/DBP.0b013e3181c3c3a8. No abstract available.

PMID:
19996904
37.

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.

Caers J, Hose D, Kuipers I, Bos TJ, Van Valckenborgh E, Menu E, De Bruyne E, Goldschmidt H, Van Camp B, Klein B, Vanderkerken K.

Haematologica. 2010 Jan;95(1):163-7. doi: 10.3324/haematol.2009.006411. Epub 2009 Oct 14.

38.

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K.

Cancer Res. 2009 Jul 1;69(13):5307-11. doi: 10.1158/0008-5472.CAN-08-4472. Epub 2009 Jun 16.

39.

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, King P, Vande Broek I, De Raeve H, Van Camp B, Croucher P, Vanderkerken K.

Leukemia. 2009 Oct;23(10):1894-903. doi: 10.1038/leu.2009.121. Epub 2009 Jun 4.

PMID:
19494837
40.

The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.

Menu E, van Valckenborgh E, van Camp B, Vanderkerken K.

Arch Physiol Biochem. 2009 May;115(2):49-57. doi: 10.1080/13813450902736583. Review.

PMID:
19234898
41.

Outbreak of norovirus infection among river rafters associated with packaged delicatessen meat, Grand Canyon, 2005.

Malek M, Barzilay E, Kramer A, Camp B, Jaykus LA, Escudero-Abarca B, Derrick G, White P, Gerba C, Higgins C, Vinje J, Glass R, Lynch M, Widdowson MA.

Clin Infect Dis. 2009 Jan 1;48(1):31-7. doi: 10.1086/594118.

PMID:
19025489
42.

Multiple myeloma--an update on diagnosis and treatment.

Caers J, Vande broek I, De Raeve H, Michaux L, Trullemans F, Schots R, Van Camp B, Vanderkerken K.

Eur J Haematol. 2008 Nov;81(5):329-43. doi: 10.1111/j.1600-0609.2008.01127.x. Epub 2008 Sep 13. Review.

PMID:
18637123
43.

Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma.

Caers J, Menu E, De Raeve H, Lepage D, Van Valckenborgh E, Van Camp B, Alvarez E, Vanderkerken K.

Br J Cancer. 2008 Jun 17;98(12):1966-74. doi: 10.1038/sj.bjc.6604388. Epub 2008 Jun 3.

44.

Norms, who needs them?

Camp BW.

Dev Med Child Neurol. 2008 Jun;50(6):407. doi: 10.1111/j.1469-8749.2008.00407.x. No abstract available.

45.

Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.

De Bruyne E, Bos TJ, Asosingh K, Vande Broek I, Menu E, Van Valckenborgh E, Atadja P, Coiteux V, Leleu X, Thielemans K, Van Camp B, Vanderkerken K, Van Riet I.

Clin Cancer Res. 2008 May 15;14(10):2918-26. doi: 10.1158/1078-0432.CCR-07-4489.

46.

Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment.

Caers J, Van Valckenborgh E, Menu E, Van Camp B, Vanderkerken K.

Bull Cancer. 2008 Mar;95(3):301-13. doi: 10.1684/bdc.2008.0600. Review.

48.

Extravasation and homing mechanisms in multiple myeloma.

Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I.

Clin Exp Metastasis. 2008;25(4):325-34. Epub 2007 Oct 19. Review.

PMID:
17952614
49.

Evaluating bias in validity studies of developmental/behavioral screening tests.

Camp BW.

J Dev Behav Pediatr. 2007 Jun;28(3):234-40. Review.

PMID:
17565292
50.

Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.

Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K, Van Camp B, Croucher P, Vanderkerken K.

Int J Cancer. 2007 Oct 15;121(8):1857-61.

Supplemental Content

Support Center